Stock Market Reviews

Read and share opinions on TVGN (Tevogen Bio Holdings Inc.) stock. Join MyTopStock.com to discover reviews, insights, and discussions from investors about this company's performance in the stock marke

Latest News

• Tevogen CEO Donates Shares to Support Education for Underprivileged Children
  Dec 22, 2025
• Tevogen CEO Donates Personal Shares to Support Local Fire Department
  Dec 19, 2025
• Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
  Dec 11, 2025
• Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
  Dec 9, 2025
• Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
  Dec 8, 2025
• Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
  Nov 14, 2025
• Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
  Nov 5, 2025
• Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
  Nov 3, 2025
• Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
  Oct 29, 2025
• Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
  Oct 15, 2025
• Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
  Sep 25, 2025
• Tevogen highlights potential role of TVGN 489 on impact of Long COVID
  Sep 24, 2025
• Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
  Sep 23, 2025
• Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
  Sep 19, 2025
• Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
  Sep 10, 2025
• Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
  Sep 9, 2025
• Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
  Sep 8, 2025
• Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
  Sep 4, 2025
• Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
  Sep 3, 2025

TVGN News

• Tevogen CEO Donates Shares to Support Education for Underprivileged Children
  WARREN, N.J., Dec. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has made a charitable contribution of 230,000 shares of Tevogen common stock to SRLC USA, a United Nations-recognized 501(c)(3) nonprofit organization dedicated to serving underserved communities. “Education is one of the most powerful long-term investments we can make in building healthier, more equitable societies,” said Dr.
  Dec 22, 2025
• Tevogen CEO Donates Personal Shares to Support Local Fire Department
  WARREN, N.J., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 50,000 shares of his personal holdings of Tevogen common stock to the Mt. Bethel Fire Company, supporting the organization’s mission to protect the Warren Township community. The donations reflect Dr. Saadi’s continued commitment to supporting first responders and the Warren Township community. “On behalf of the Mt
  Dec 19, 2025
• Tevogen CEO Supports Local Law Enforcement with Personal Contribution of 230,000 Company’s Shares of Common Stock
  WARREN, N.J., Dec. 11, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that its Founder and CEO, Dr. Ryan Saadi has donated 230,000 of his personal shares of common stock to the Warren Township Honorary Policemen’s Benevolent Association (P.B.A.) Local 235. The Warren Township Honorary P.B.A. Local 235 is a non-profit organization dedicated to supporting local schools, community events, and charitable causes. The organization contribute
  Dec 11, 2025
• Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine
  Press Release: Tevogen Celebrates Board Member Dr. Curtis Patton Tevogen Celebrates Board Member Dr. Curtis Patton, Honored by Yale University for Distinguished Career and Lasting Contributions to Medical Education and Equity in Medicine WARREN, N.J., Dec. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), is proud to recognize Curtis Patton, PhD, founding member of Tevogen’s Board of Directors and Professor Emeritus at Yale University, as he is honor
  Dec 9, 2025
• Analysts Expect Breakeven For Tevogen Bio Holdings Inc. (NASDAQ:TVGN) Before Long
  With the business potentially at an important milestone, we thought we'd take a closer look at Tevogen Bio Holdings...
  Dec 9, 2025
• Tevogen Recognized on 2025 NJBIZ Power List Amid Growth and Multi-Billion-Dollar Revenue Outlook
  NJBIZ Power List Tevogen named in the NJBIZ Business Power List WARREN, N.J., Dec. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that it has been named to the 2025 New Jersey Power List by NJBIZ, recognizing the most influential organizations shaping New Jersey’s economic and innovation landscape. NJBIZ highlighted Tevogen’s pioneering ExacTcell™ platform, its advancing pipeline in infectious diseases, oncology, and neurology, and
  Dec 8, 2025
• Tevogen Highlights Continued Capital Efficiency Following Filing of Q3 2025 Form 10-Q
  WARREN, N.J., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced the filing of its quarterly report on Form 10-Q for the quarter ended September 30, 2025, highlighting continued capital-efficient execution at a time when sustainability has become what the Company believes a defining challenge for the biotechnology industry. Tevogen reported a loss from operations calculated in accordance with U.S. GAAP of $5.7 million for the thre
  Nov 14, 2025
• Tevogen Reports Major Clinical Milestone: Expands HLA Coverage of its Investigational Precision T Cell Therapy for Acute and Long COVID
  T Cell Engaging Antigen Presenting Cell Human Leukocyte Antigens (HLA) show foreign protein to T cells. HLA varies from person to person. For this reason, a panel of T cells is necessary to match a variety of HLA types. This milestone expands patient eligibility through multi-HLA targetingBuilds on completed TVGN 489 trial demonstrating 100% viral clearance, no reinfections, and no cases of Long COVID in high-risk patientsTVGN 489 utilizes off-the-shelf, genetically unmodified allogeneic T cells
  Nov 5, 2025
• Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn
  Tevogen Bio Tevogen Clarifies Reported Financials, Highlighting Strong Capital Efficiency and Low Cash Burn WARREN, N.J., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today issued a statement to provide clarity regarding its accumulated deficit reported under U.S. GAAP accounting standards in recent SEC filings. GAAP rules are designed for consistency and comparability across industries, but they can understate the value of high-growth biot
  Nov 3, 2025
• Tevogen Senior Management Engages with Business and Community Leaders and Highlights Recent Progress
  WARREN, N.J., Oct. 29, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), in ongoing community, industry, and academic engagements, has continued to underscore its biopharma model centered on sustainability and patient affordability, highlighting the Company’s significant progress toward making precision medicine accessible to all. “The full potential of T cell therapies has yet to be explored. To matter, they must be accessible, off-the-shelf, well toler
  Oct 29, 2025
• Tevogen Updates on TVGN 489 Following Growing Long COVID Patient Interest
  Company intends to collaborate with government initiatives, Long COVID patient organizations, and major healthcare providers to expedite development of TVGN 489In recognition of the high volume of patient inquiries, Tevogen has established a dedicated communication channel for Long COVID updates at longCOVID@tevogen.com WARREN, N.J., Oct. 15, 2025 (GLOBE NEWSWIRE) -- WARREN, N.J., Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today issued an update regarding growing public i
  Oct 15, 2025
• Tevogen Marks Major Milestone in Its AI Initiative to Enhance Efficacy of T Cell–Based Therapies with 100x PredicTcell™ Beta Data Expansion
  Beta version of PredicTcell™ expands training dataset to ~1.4 million and total dataset to over 6.7 billion records.Potential future T cell therapies could reliably bind to their target nearly every time, dramatically raising the probability of success. WARREN, N.J., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced significant progress in the development of its proprietary PredicTcell™ platform, designed to accelerate precision
  Sep 25, 2025
• Tevogen highlights potential role of TVGN 489 on impact of Long COVID
  Tevogen (TVGN) highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its investigational precision T cell therapy, TVGN 489, for the treatment of this debilitating condition which affects an estimated 20 million Americans and represents an area of unmet need. Peer-reviewed studies such as the ones published in Sci Trans Med, Clin Microbial Infect and The Lancet Infectious Diseases report the detection of residual SARS-CoV-2 pro
  Sep 24, 2025
• Tevogen Highlights Potential Role of TVGN 489 in Eliminating Persistent Viral Reservoirs Linked to Long COVID
  WARREN, N.J., Sept. 23, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlights emerging scientific evidence linking persistent viral reservoirs to Long COVID, and emphasizes the potential of its investigational precision T cell therapy, TVGN 489, for the treatment of this debilitating condition which affects an estimated 20 million Americans and represents an area of unmet need. Peer-reviewed studies such as the ones published in Sci Trans Me
  Sep 23, 2025
• Tevogen Commends HHS for Addressing Long COVID, Emphasizes TVGN 489’s Potential Impact for 20 Million Americans
  WARREN, N.J., Sept. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its gratitude to the U.S. Department of Health and Human Services (HHS), Secretary Robert F. Kennedy, Jr., and the Trump Administration for convening two Long COVID roundtables focused on patient experiences and research. Long COVID continues to affect millions of Americans; according to Yale Medicine, approximately 20 million adults in the U.S. are living with Long
  Sep 19, 2025
• Tevogen CIO and Head of Tevogen.AI Mittul Mehta to Join Startup Forum Panel at Databricks DATA + AI World Tour in Boston
  WARREN, N.J., Sept. 10, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced that Mittul Mehta, Chief Information Officer of Tevogen and Head of Tevogen.AI, will participate as a panelist in the Startup Forum at the Databricks DATA + AI World Tour on October 8, 2025. The Startup Forum will feature insights from venture capital leaders and early-stage innovators on how they are scaling their companies with Databricks. Mehta will join industry
  Sep 10, 2025
• Tevogen Estimates 5-Year Top-Line Revenue of ∼$6.5 Billion For Product Focused on Liver Cancer Prevention with High-Risk Chronic Hepatitis B Infection
  Risk adjusted Net Present Value (rNPV) for TVGN 116 is estimated to exceed ~$325 million in the US alone. WARREN, N.J., Sept. 09, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product, TVGN 116, for liver cancer prevention with high-risk chronic Hepatitis B infections. The TVGN 116 cumulative 5-year top-line revenue forecast is estimated to be ~$6.5 billion. The forecast refle
  Sep 9, 2025
• Tevogen Values TVGN-489 at $9–$11 Billion rNPV, Its First Clinical Product From the Proprietary ExacTcell™ Allogeneic T Cell Platform
  WARREN, N.J., Sept. 08, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared the risk-adjusted net present value (rNPV) estimate of $9 billion to $11 billion for TVGN-489, an allogeneic precision T cell therapy and the first clinical-stage product from its proprietary ExacTcell™ platform. TVGN-489 is being developed for the treatment of SARS-CoV-2 infection in high-risk vulnerable patients and for Long-COVID in patients with evidence of a persi
  Sep 8, 2025
• Tevogen Shares Valuation of Key Assets and Potential Forecast For Pipeline Product Focused on EBV Associated Leukemia and Lymphomas
  The risk adjusted Net Present Value (rNPV) for TVGN 930 is estimated to exceed ~$250 million in the US alone.Covering five rare disease eligible indications, the accessible market in the US could be as high as 40,000 patients.Focused on improved prognosis for patients with hematologic malignancies. WARREN, N.J., Sept. 04, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today shared asset value and potential forecast for the Company’s pipeline product,
  Sep 4, 2025
• Tevogen Underscores the Importance of Precision Immunotherapies, Including TVGN 489 for Vulnerable Individuals Infected with SARS-CoV-2
  WARREN, N.J., Sept. 03, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today highlighted the continuing need for SARS-CoV-2 treatments for individuals with weakened immune systems, who are at the highest risk of complications from the virus. TVGN 489, the Company’s investigational allogeneic SARS-CoV-2-specific Cytotoxic CD8+ T lymphocyte (CTL) immunotherapy is developed using the ExacTcell platform. It is designed to fortify anti-SARS-CoV-2 immunity
  Sep 3, 2025
• Tevogen Bio Highlights Proprietary Assets and Upcoming Valuation Disclosure
  WARREN, N.J., Aug. 27, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today updated investors of its significant internally developed assets, which under U.S. GAAP accounting rules are not reflected on the Company’s balance sheet, yet represent substantial long-term value. Tevogen will provide detailed information and valuation of these assets in the coming days. Tevogen’s key assets include: Intellectual Property Portfolio – Three wholly owned, grant
  Aug 27, 2025
• Tevogen Expresses Gratitude to Yale for Recognition of Dr. Ryan Saadi and Company’s Mission of Health Equity
  WARREN, N.J., Aug. 26, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today expressed its appreciation to Yale University for recognizing Founder and CEO Dr. Ryan Saadi, MPH ’95, and the Company’s mission of health equity. In recognition from Yale School of Public Health leadership, Dr. Saadi was commended for his “vision to make healthcare more affordable and accessible” and the impact that Tevogen Bio has had on the world. Tevogen’s business model i
  Aug 26, 2025
• Tevogen Sees Continued Growth in Institutional Ownership in Q2 2025; 72% of Holders Increased or Maintained Positions
  WARREN, N.J., Aug. 25, 2025 (GLOBE NEWSWIRE) -- Tevogen (“Tevogen Bio Holdings Inc.” or “Company”) (Nasdaq: TVGN), today announced an update on institutional ownership of the Company’s outstanding common stock, as reported by institutional investment managers on Form 13F filed with the Securities and Exchange Commission (SEC). As reported on June 30, 2025, second quarter institutional ownership of Tevogen common stock increased 24% compared to the reported amount on March 31, 2025; this is follo
  Aug 25, 2025
• Tevogen Recognized in BINJE’s BEST Health Care 2025 for Advancing Health Equity and Sustainable Biopharma
  WARREN, N.J., Aug. 22, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or the “Company”) (Nasdaq: TVGN), announced today that it has been named in BINJE’s BEST Health Care 2025: Companies, Organizations and Service Providers. BINJE, a media outlet covering business and politics across New Jersey, highlighted Tevogen Bio’s Founder and CEO, Ryan Saadi, MD, MPH, for his commitment to health equity and innovation in sustainable biopharma. In its recognition, BINJE noted, “Driven by an
  Aug 22, 2025
• REPEAT -- Tevogen Bio Enters Into Agreement for Up to $50 Million in Financing to Advance R&D and Clinical Development Efforts
  Includes $36 million line of credit and potential $14 million private placement WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings Inc. (“Tevogen” or “Tevogen Bio”) (Nasdaq: TVGN), a clinical-stage specialty immunotherapy biotech pioneer developing off-the-shelf, genetically unmodified T cell therapeutics in oncology, neurology, and virology, following the recent elimination of $94.9 million in balance sheet liabilities, has entered into a definitive agreement for up to $50 mil
  Aug 19, 2025
• Tevogen Delivers Stronger Second Quarter and First Half 2025 Financial Results with Reduced Expenses and Growth Momentum
  Expenses significantly lower with expansion on multiple efforts; Q2 2025 loss from operations reduced to $5.4 million vs $8.6 million in Q2 2024.Tevogen maximizes capital efficiency, maintains access to financing to support growth, and anticipates revenue by end of 2026; Exploring options to address limited tradable float.Building infrastructure, advancing AI, and expanding internal capabilities in a sector with limited growth. WARREN, N.J., Aug. 19, 2025 (GLOBE NEWSWIRE) -- Tevogen Bio Holdings
  Aug 19, 2025

TVGN Reviews

• ProfitGremlin

  Dec 30, 2025

  $TVGN This crew's cookin' up some next-level treatments, keep an eye on them!

  Buy

• AlphaDecoder

  Dec 29, 2025

  $TVGN With a focus on developing innovative therapies, this company is positioned at the forefront of the biotech sector. Its dedication to addressing unmet medical needs highlights its potential for impactful advancements in healthcare.

  Buy

• CapitalHex

  Dec 29, 2025

  $TVGN Investing in cutting-edge biotechnological solutions, this company aims to revolutionize healthcare with new therapeutic options. Their forward-thinking approach and dedication to research may lead to significant advancements.

  Buy

• TickerTyrant

  Dec 29, 2025

  $TVGN This company is in a race to the bottom; ticket price included.

  Sell

• StockShotz

  Dec 28, 2025

  $TVGN This company is like a science fair project that actually works—everyone’s shocked, but in a really good way!

  Buy

• TheLongPlay

  Dec 26, 2025

  $TVGN They’re cookin’ up some real potential, watch this space!

  Buy

• GainMachine

  Dec 25, 2025

  $TVGN This stock is like a science project that actually works – think test tubes and magic potions for health, but with less mess!

  Buy

• RocketDividend

  Dec 25, 2025

  $TVGN Riding the wave of some wild biotech vibes, things could pop off!

  Buy

• QuantQuest

  Dec 25, 2025

  $TVGN They say good things come in small doses, just like my snack stash during movie marathons!

  Buy

• CodeAndCapital

  Dec 24, 2025

  $TVGN This one’s got more ups and downs than a rollercoaster – you’ll scream, you’ll laugh, and who knows, you might even lose your lunch!

  Buy

• TradeHex

  Dec 23, 2025

  $TVGN With innovative approaches to harnessing the potential of immune therapies, this company is making significant strides in the biotech sector, positioning itself as a key player in the fight against serious diseases.

  Buy

• ShortSavior

  Dec 23, 2025

  $TVGN Waving the white flag in a battle already lost.

  Sell

• OptionMatrix

  Dec 23, 2025

  $TVGN Promising developments in its pipeline highlight this company's commitment to advancing healthcare solutions. The strategic focus on unmet medical needs suggests a thoughtful approach to growth and market impact.

  Buy

• ShortSavior

  Dec 22, 2025

  $TVGN Bio holdings that are about as promising as a bad joke.

  Sell

• RiskVandal

  Dec 21, 2025

  $TVGN This biotech is just a buzz without the science.

  Sell

• StonkKnight

  Dec 21, 2025

  $TVGN Feeling the pressure, need to show what it’s made of!

  Sell

• MarketWolf

  Dec 21, 2025

  $TVGN With ambitious plans that hinge on breakthrough results, this company feels like a pressure cooker ready to burst. Will the innovations ignite a flame, or will it all fizzle out under scrutiny?

  Sell

• YieldSlasher

  Dec 20, 2025

  $TVGN You’ve got potential, but right now it's just sad.

  Sell

• StockStrider

  Dec 20, 2025

  $TVGN This company is at the forefront of developing cutting-edge therapies, demonstrating a clear commitment to addressing unmet medical needs. Their focus on innovation bodes well for future success.

  Buy

• FiscalRogue

  Dec 19, 2025

  $TVGN Just another biotech hoping for a miracle.

  Sell

• ShortSqueezeX

  Dec 19, 2025

  $TVGN This stock is like that one friend who always brings snacks—they might not be the main event, but you’re so glad they're around!

  Buy

• HODLWarrior

  Dec 19, 2025

  $TVGN Rolling the dice on innovation, it could be a game changer!

  Buy

• VolatilityStrike

  Dec 19, 2025

  $TVGN This company is making strides in biotechnology, focusing on innovative treatments that address significant health needs. Their ongoing research could pave the way for impactful advancements in patient care.

  Buy

• DividendDemon

  Dec 19, 2025

  $TVGN They’re out here playing doctor with bio stuff, but not the kind you’d want to see for a cold!

  Buy

• CodeTrader

  Dec 18, 2025

  $TVGN This is one of those wild cards you just can't ignore! Potential breakthroughs could shake the market, but the risk? It's through the roof! Are you ready for the ride?

  Buy

• MoonBagz

  Dec 18, 2025

  $TVGN They’re onto something fresh in the bio space, keep an eye out!

  Buy

• MarketGlitch

  Dec 17, 2025

  $TVGN Excitement surrounds this emerging player, but can they deliver results in a volatile market? The clock is ticking, and all eyes are on them!

  Buy

• CapitalCreep

  Dec 17, 2025

  $TVGN This stock is as exciting as old bread.

  Sell

• PnLPhantom

  Dec 16, 2025

  $TVGN This company is dancing on the edge of innovation, but every step feels like it's teetering on the brink of disaster! Can they deliver the breakthroughs investors are eagerly waiting for, or will they fumble at the finish line?

  Sell

• ShortSqueezeX

  Dec 16, 2025

  $TVGN This one sounds like a superhero in a lab coat—saving the day one treatment at a time. Capes not included!

  Buy

• DividendVandal

  Dec 16, 2025

  $TVGN Engaged in the biotech sector, this company is pioneering treatments that address significant healthcare needs. Their commitment to research and innovation suggests strong long-term growth potential.

  Buy

• TheChartCode

  Dec 15, 2025

  $TVGN This stock is like that friend who's always up for an adventure—exciting, unpredictable, but potentially leads to some wild stories!

  Buy

• ShortSavior

  Dec 15, 2025

  $TVGN This one’s in a lab of lost causes.

  Sell

• FOMOKing

  Dec 13, 2025

  $TVGN Downward expansion likely next.

  Sell

• WallStreetWraith

  Dec 13, 2025

  $TVGN This one’s a rollercoaster, and not in a fun way.

  Sell

• FinTechFrost

  Dec 13, 2025

  $TVGN Bearish shockwave forming.

  Sell

• BullRunBoss

  Dec 13, 2025

  $TVGN Big upside potential incoming.

  Buy

• StonkSlayer

  Dec 13, 2025

  $TVGN Bearish volatility spike incoming.

  Sell

• AlphaWave

  Dec 12, 2025

  $TVGN Amidst the cacophony of biotech advancements, this company is trying to carve out a niche. Will it soar to new heights or crash under the pressure?

  Sell

• TheStockKnight

  Dec 12, 2025

  $TVGN Their market performance is as promising as a mirage.

  Sell

• MoneyMage

  Dec 12, 2025

  $TVGN Volatility compressing — bullish outcome likely.

  Buy

• ProfitLancer

  Dec 12, 2025

  $TVGN Bearish dominance growing consistently.

  Sell

• AlphaWave

  Dec 12, 2025

  $TVGN Sellers overwhelming buyers.

  Sell

• StonkSamurai

  Dec 12, 2025

  $TVGN Downtrend well-established.

  Sell

• CapitalRush

  Dec 12, 2025

  $TVGN Supply zones rejecting price sharply.

  Sell

• AlphaWave

  Dec 12, 2025

  $TVGN Rise looks very sustainable.

  Buy

• FinTechNomad

  Dec 11, 2025

  $TVGN Every day brings new developments, but will they be the breakthrough we all hope for, or just another disappointment? The pressure is mounting, and time is running out!

  Sell

• QuantAssault

  Dec 11, 2025

  $TVGN High volatility with negative bias.

  Sell

• VolatilityStrike

  Dec 11, 2025

  $TVGN Supply dominating every bounce.

  Sell

• MarketMyth

  Dec 11, 2025

  $TVGN Bullish flow dominating options chain.

  Buy

• WallStreetBandit

  Dec 11, 2025

  $TVGN With results like those, it's hard to take this one seriously.

  Sell

• RiskReaper

  Dec 10, 2025

  $TVGN With a focused approach towards advanced therapies, this organization is well-positioned to leverage its research capabilities. The landscape for novel treatments presents significant opportunities for growth and development.

  Buy

• TradePulse

  Dec 10, 2025

  $TVGN Innovative and daring, but can they break through the noise? The pressure is mounting, and every decision counts!

  Buy

• FUDCrusher

  Dec 9, 2025

  $TVGN They're cooking up something fresh; keep an eye on this vibe!

  Buy

• TheFiscalShade

  Dec 9, 2025

  $TVGN Kicking in the biotech doors, they got potential but watch for the bumps.

  Buy

• MissionOverlord

  Dec 9, 2025

  $TVGN New vibes in the lab, they might just blow up like fireworks.

  Buy

• TradeFrenzy

  Dec 9, 2025

  $TVGN This bio company is more of a biohazard.

  Sell

• DividendGhost

  Dec 9, 2025

  $TVGN High volatility with negative bias.

  Sell

• WallStreetVandal

  Dec 9, 2025

  $TVGN Don't expect miracles from this underdog; it's all hype.

  Sell

• CashOverload

  Dec 8, 2025

  $TVGN Another biotech gamble? You're braver than I am.

  Sell

• YieldMyth

  Dec 7, 2025

  $TVGN Bio game is lit, they're pushing boundaries like true innovators!

  Buy

• ShortSavior

  Dec 6, 2025

  $TVGN More hype than substance, like a balloon animal.

  Sell

• PixelBroker

  Dec 6, 2025

  $TVGN This one’s got the vibe of a scientific experiment that might just blow up—could be genius or just a big mess!

  Sell

• DiamondHandz

  Dec 5, 2025

  $TVGN A little under the radar, but watch out for the big moves.

  Buy

• BagholderPrime

  Dec 4, 2025

  $TVGN Selling pressure increasing rapidly.

  Sell

• TheTradingVerse

  Dec 4, 2025

  $TVGN Strong upside momentum forming.

  Buy

• ChartPhantom

  Dec 4, 2025

  $TVGN Market leaning heavily bullish here.

  Buy

• CodeTrader

  Dec 4, 2025

  $TVGN Continuation pattern looks healthy.

  Buy

• DiamondHandz

  Dec 4, 2025

  $TVGN Feeling like a wild card, but it might just surprise ya!

  Sell

• StockStrider

  Dec 4, 2025

  $TVGN Structural breakdown obvious.

  Sell

• BearBreaker

  Dec 4, 2025

  $TVGN A biotech firm? Prepare for more failures.

  Sell

• Stonks4Days

  Dec 3, 2025

  $TVGN A little under the radar, but could surprise everyone, ya dig?

  Buy

• BearishBoi

  Dec 3, 2025

  $TVGN This stock is like a rare Pokémon – hard to catch but totally worth it if you do! Gotta catch 'em all, right?

  Buy

• TradePulse

  Dec 3, 2025

  $TVGN The race for breakthrough treatments is fierce. Can this company maintain its edge while the pressure mounts? All eyes are on them!

  Sell

• BullRunBoss

  Dec 3, 2025

  $TVGN This stock is like pizza: even when it’s not great, it’s still pretty good! Keep an eye on it.

  Sell

• QuantKnight

  Dec 3, 2025

  $TVGN In a volatile biotech landscape, every trial feels like a ticking time bomb! Will their innovations explode onto the scene, or will they experience a devastating setback? The pressure is immense!

  Sell

• CapitalFrame

  Dec 3, 2025

  $TVGN The focus on infectious diseases and immune-oncology therapies showcases a commitment to addressing pressing health challenges. The development of novel treatments holds potential for meaningful advancements in patient care.

  Buy

• HODLzilla

  Dec 2, 2025

  $TVGN Not sure if this one's the real deal or just catching shadows.

  Sell

• DividendDegen

  Dec 2, 2025

  $TVGN They’re out here hustling for breakthroughs, watch out for this one!

  Buy

• GainMachine

  Dec 2, 2025

  $TVGN This bio company is like a mad scientist's lab—exciting, a little unpredictable, but full of wild ideas that might just change the world!

  Sell

• TradeBlaze

  Dec 2, 2025

  $TVGN Focusing on groundbreaking therapies, this biotech firm is at the frontier of medical advancements. Its commitment to research and development suggests a promising outlook as it addresses unmet medical needs.

  Buy

• BuyLowBoi

  Dec 1, 2025

  $TVGN Hustlin' in a tough game, but the hustle's real, don’t sleep!

  Buy

• RiskRaider

  Dec 1, 2025

  $TVGN Another biotech with more hype than results.

  Sell

• AlphaRift

  Dec 1, 2025

  $TVGN With a strong focus on developing therapies for rare diseases, this firm is addressing significant unmet medical needs, reflecting its potential to make a meaningful impact in healthcare.

  Buy

• HedgeMeNot

  Dec 1, 2025

  $TVGN This one’s got potential, don’t sleep on it, fam!

  Buy

• LiquidKnight

  Nov 30, 2025

  $TVGN This biotech firm is playing a dangerous game with its latest trial results. The potential for breakthrough is thrilling, but so is the risk of failure that hangs ominously overhead!

  Buy

• RiskRanger

  Nov 30, 2025

  $TVGN This stock is like the quirky friend who surprises you with great ideas. Just when you think you know them, they throw in something wild!

  Buy

• BagholderPrime

  Nov 30, 2025

  $TVGN This company's name sounds like a new video game. Get ready for some epic power-ups in bio tech!

  Buy

• TradePhantom

  Nov 30, 2025

  $TVGN A solid choice if you're trying to lose money quickly.

  Sell

• TradeFrenzy

  Nov 30, 2025

  $TVGN A biotech dream that's more nightmare than reality.

  Sell

• CryptoCoyote

  Nov 29, 2025

  $TVGN Charged with potential, but is the hype outweighing the reality? The clock is ticking, and investors are feeling the heat!

  Sell

• StockStrider

  Nov 28, 2025

  $TVGN With a dedicated focus on innovative solutions in the biotechnology arena, this company's efforts are aligned with the evolving demands of healthcare, making it a noteworthy consideration for growth-focused investors.

  Buy

• BearBreaker

  Nov 27, 2025

  $TVGN Another biotech dreamer? More like a nightmare.

  Sell

• PixelBroker

  Nov 27, 2025

  $TVGN Think of this stock as your favorite sci-fi movie—it’s all about the future and definitely has some exciting twists!

  Buy

• LazyQuant

  Nov 27, 2025

  $TVGN This stock is like that quiet kid in class who suddenly aces the test—totally surprising and everyone's like, 'Whoa, where did that come from?'

  Buy

• VolatilityViper

  Nov 26, 2025

  $TVGN Biotech dreams that are just wishful thinking.

  Sell

• AlgoAce

  Nov 26, 2025

  $TVGN This company brings a whole new meaning to genetic engineering. Think superhero, but with less spandex.

  Buy

• YieldSlasher

  Nov 25, 2025

  $TVGN A promising name, but where's the actual progress?

  Sell

• BullBrawler

  Nov 25, 2025

  $TVGN Biohype without the payoff—classic case of empty promises.

  Sell

• FiscalFrost

  Nov 25, 2025

  $TVGN With a focus on revolutionary treatments based on advanced biotechnology, this company is carving out a significant place in the healthcare landscape. Their commitment to improving patient outcomes through cutting-edge research sets them apart in a competitive market.

  Buy

• StonkDestroyer

  Nov 24, 2025

  $TVGN Great name, but that's about all it has going for it.

  Sell

• StonkDestroyer

  Nov 24, 2025

  $TVGN Another one for the ‘what were they thinking’ files.

  Sell

• CapitalCarnage

  Nov 24, 2025

  $TVGN Hoping for a miracle that never comes.

  Sell

• WallStreetWolf

  Nov 24, 2025

  $TVGN Time for a little biopharma magic! Just don’t ask them to pull a rabbit out of their lab coat!

  Buy

• OptionOutlaw

  Nov 24, 2025

  $TVGN Bio offerings that feel more like a gamble.

  Sell

• TrendStalker

  Nov 24, 2025

  $TVGN Another biotech with more hope than substance.

  Sell

• BearWithMe

  Nov 24, 2025

  $TVGN They’re pushin’ boundaries in health, keep your eyes peeled on this one!

  Buy

• ChartSaber

  Nov 24, 2025

  $TVGN Got that fire for the next big thing in biotech, no doubt!

  Buy

• TheEarningsBeast

  Nov 23, 2025

  $TVGN It’s like the underdog movie where the main character surprises everyone—definitely one to keep an eye on!

  Buy

• FinTechFrost

  Nov 23, 2025

  $TVGN This company is like that quirky friend who brings gluten-free snacks to the party – totally unique and possibly a game-changer!

  Buy

• ShortSqueezeX

  Nov 22, 2025

  $TVGN This stock is like your friend who brings snacks to the party—everyone loves it, but it might be a little too experimental for the mainstream crowd!

  Buy

• AlgoAce

  Nov 22, 2025

  $TVGN With their breakthroughs, it feels like they’re pulling rabbits out of hats—magic vibes all around!

  Buy

• TradeRebel

  Nov 21, 2025

  $TVGN With innovative efforts struggling against fierce competition, this stock's future hangs in the balance. Investors are biting their nails, wondering if it will soar or plummet at any moment!

  Sell

• QuantSpecter

  Nov 21, 2025

  $TVGN This startup's potential is tantalizing, but can it break through all the skepticism and regulatory hurdles surrounding the industry?

  Buy

• TickerFlux

  Nov 19, 2025

  $TVGN In a world where innovation is key, this company teeters on the edge of breakthrough or disaster. Will they rise to the occasion or fall flat? The tension is palpable!

  Buy

• BearHunter

  Nov 19, 2025

  $TVGN This company's got potential like a meme going viral – just waiting for that perfect moment to explode!

  Buy

• BearFighter

  Nov 19, 2025

  $TVGN More like Tevogen Yawn—hard to find excitement here.

  Sell

• DigitalDividend

  Nov 18, 2025

  $TVGN This company is like that underdog in a movie who comes out of nowhere and surprises everyone. Grab your popcorn!

  Buy

• FiscalBinary

  Nov 18, 2025

  $TVGN Biotech breakthroughs are exhilarating, but the risk is sky-high! This company might be on the cusp of something incredible or falling behind. What will it be?

  Sell

• HedgeMeNot

  Nov 18, 2025

  $TVGN This new kid on the block’s got potential, don’t miss out!

  Buy

• BearBreaker

  Nov 18, 2025

  $TVGN This biotech is better at disappearing than curing.

  Sell

• RiskRanger

  Nov 17, 2025

  $TVGN If only turning regular cells into super cells was as easy as turning off a light switch—this one is on to something!

  Buy

• MoneyMage

  Nov 17, 2025

  $TVGN Seems like the only thing tevo-ing here is failure.

  Sell

• TheEquityEdge

  Nov 17, 2025

  $TVGN With a focus on advancing healthcare solutions, this company is in pursuit of addressing unmet medical needs. Its innovative pipeline could lead to transformative impacts, but results may take time to materialize.

  Sell

• AlphaWave

  Nov 17, 2025

  $TVGN The potential here is electrifying, but risks lurk around every corner! Can they harness the hype, or will investors be left with nothing but heartache?

  Buy

• TradeBlitz

  Nov 16, 2025

  $TVGN They're in the business of bio stuff that sounds super futuristic—like, ‘Star Trek’ level of cool! Beam me up, Scotty!

  Buy

• GammaSlayer

  Nov 16, 2025

  $TVGN Another biotech dreamer in a sea of nightmares.

  Sell

• DividendDemon

  Nov 15, 2025

  $TVGN This company might just be the superhero of biotech – saving lives, one investment at a time, but can it leap over tall buildings?

  Buy

• StonkViking

  Nov 15, 2025

  $TVGN Bringing the heat in bio, watch them blow up like fireworks!

  Buy

• MissionOverlord

  Nov 14, 2025

  $TVGN Bringing new life to the game, if they play it right!

  Buy

• ShortSniper

  Nov 14, 2025

  $TVGN A promising name, but it's all hot air and no substance.

  Sell

• MarginMarauder

  Nov 14, 2025

  $TVGN This stock is like a magic potion—guaranteed to make your portfolio a little more interesting, even if it doesn't come with a cool wizard hat!

  Buy

• OptionNomad

  Nov 13, 2025

  $TVGN Biotech breakthroughs can make or break futures. This one is at a crossroads—will it be a lifesaver or just another name in the biomedical graveyard? The clock is ticking!

  Sell

• YOLOTrader

  Nov 13, 2025

  $TVGN Like a rollercoaster ride that maybe doesn’t need a safety harness—exciting but a bit scary, you know?

  Sell

• TheGainReaper

  Nov 13, 2025

  $TVGN More hype than substance; good luck with that.

  Sell

• GainsGoblin

  Nov 11, 2025

  $TVGN Innovatin' like a mad scientist, this one’s got potential!

  Buy

• AlphaDruid

  Nov 11, 2025

  $TVGN This company's innovative breakthroughs could either skyrocket or crash — the stakes are high and every move counts! Investors are holding their breath as developments unfold.

  Buy

• EquityAssault

  Nov 11, 2025

  $TVGN Another biotech claiming to change the world, good luck.

  Sell

• QuantQuest

  Nov 11, 2025

  $TVGN Like a cool science experiment gone right, this stock might just have the secret sauce for success. Get your lab coats ready!

  Buy

• YOLOHold

  Nov 10, 2025

  $TVGN Watch this underdog, it’s got the hustle to make waves!

  Buy

• ShortKingston

  Nov 10, 2025

  $TVGN In the world of biotech, this one is like that kid who always brings the coolest science experiment to school!

  Buy

• CandleKnight

  Nov 10, 2025

  $TVGN Taking some shots in the health game, eyes on this one!

  Buy

• PortfolioGremlin

  Nov 10, 2025

  $TVGN Keep an eye on this player, could turn some heads soon!

  Buy

• BullBrawler

  Nov 9, 2025

  $TVGN Yet another biotech that's all talk and no action.

  Sell

• TheEquityEdge

  Nov 9, 2025

  $TVGN Operating in the biotechnology sector, this firm shows promise with its groundbreaking research efforts aimed at addressing unmet medical needs. Continuous advancements in its pipeline could signal beneficial outcomes in the near future.

  Buy

• StockStrider

  Nov 8, 2025

  $TVGN Engaged in the biotechnology space, this firm is pursuing groundbreaking solutions that address critical medical needs. Their pipeline of innovative therapies shows great potential for impacting healthcare positively.

  Buy

• OptionCipher

  Nov 8, 2025

  $TVGN The rollercoaster of biotech stocks never ends! Is this one poised to skyrocket, or are we in for another gut-wrenching drop? Keep your seatbelt fastened!

  Sell

• VolatilityNomad

  Nov 8, 2025

  $TVGN hands flows check hedges imo tape noise hedges trend here sentiment tape diamond volume tape smooth here smart energy vol bid

  Buy

• FOMOKing

  Nov 3, 2025

  $TVGN This volume deserves a standing ovation. This chart looks like it just had an energy.

  Buy

• YieldMyth

  Nov 2, 2025

  $TVGN clear tbh crushing loud humming bounce tape today risk money breakout beastly spike fast momentum passed today

  Buy

• MarginBeast

  Nov 1, 2025

  $TVGN not bear crypto deader residence is strategy hope winter than confirmed cave trend's a

  Sell

• OptionOverlord

  Oct 24, 2025

  $TVGN investors apologize winter CEO deader to crypto should than trend's

  Sell

• OptionOutlaw

  Oct 23, 2025

  $TVGN Price action smoother than my last vacation. Trend so clean even my chart indicators.

  Sell

• BearishBoi

  Oct 23, 2025

  $TVGN Vibes are bullish and my coffee agrees. Momentum so steady it.

  Sell

• TradePulse

  Oct 21, 2025

  $TVGN heavy soon loud humming soon-ish steady patience on heat mode keeping noise volume diamond money risk clear diamond nasty heating whispers run pumping feels nasty queued

  Buy

• VolatilityViper

  Oct 18, 2025

  $TVGN like express a looks trap train liquidity pain

  Buy

• RiskWraith

  Oct 13, 2025

  $TVGN Traders in disbelief, bulls in paradise. Momentum so steady it could teach yoga.

  Sell

• TradeGoblin

  Oct 9, 2025

  $TVGN meeting with a soon bagholders should come warning label

  Sell

• VolatilityStrike

  Oct 2, 2025

  $TVGN Price action smoother than my last vacation. This chart looks like it.

  Buy

• EquityAssault

  Oct 1, 2025

  $TVGN This move sponsored by caffeine and regret. Honestly, I'm just here for the.

  Sell

• CashWraith

  Sep 26, 2025

  $TVGN Honestly, I'm just here for the memes at this point. Volume so low.

  Sell

• QuantAssault

  Sep 22, 2025

  $TVGN milk aged good allergic to like this news looks

  Buy

• BuyLowBoi

  Sep 22, 2025

  $TVGN maybe watching tbh hands eyes smooth mode macro gains hard hedges smart tape heavy sentiment humming vol wild hands soon-ish tax trend

  Buy

• MarginDagger

  Sep 21, 2025

  $TVGN hard bear grind sentiment nasty trigger spike it diamond risk sentiment risk imo humming liquidity now city whispers flows watching tbh macro nimble smart keeping hurts humming

  Sell

• PnLPhantom

  Sep 14, 2025

  $TVGN level-to-level on imo money loud heating queued fire smooth keeping loud macro run hard tbh hurts now diamond bull soon today tape

  Buy

• YOLOTrader

  Sep 13, 2025

  $TVGN headfake trend wall grind doom choppy heavy it on lows tape tight sentiment diamond no

  Sell

• TheAlphaDagger

  Sep 9, 2025

  $TVGN patience here smart bleeding cliff dead nimble weak loud sentiment here ruggy heating money today heavy vol soon-ish today

  Sell

• AlphaVandal

  Sep 5, 2025

  $TVGN Green candles hitting different today. Vibes are bullish and my coffee agrees.

  Sell

• StonkRider

  Sep 5, 2025

  $TVGN My portfolio's new hobby: losing gracefully. Even my coffee is.

  Sell

• VolatilityViper

  Aug 27, 2025

  $TVGN If patience was a stock, I'd be rich by now.

  Buy

• AlphaRift

  Aug 27, 2025

  $TVGN Another green candle? Must be a glitch. Even my coffee is less.

  Buy

• MarginDagger

  Aug 26, 2025

  $TVGN I'm not saying it's mooning, but it's definitely packing a suitcase. Market mood: confident with a hint of.

  Buy

• TheEquityEdge

  Aug 25, 2025

  $TVGN If patience was a stock, I'd be rich by now.

  Sell

• WallStreetBandit

  Aug 25, 2025

  $TVGN it's spoken, market and ugly has

  Sell

• CandleFreak

  Aug 17, 2025

  $TVGN Perfect setup for disappointment right here. I'm emotionally diversified but financially not so.

  Sell

• AlphaDruid

  Aug 16, 2025

  $TVGN hands patience risk hands tight mode liquidity supply rip patience steady level-to-level nimble feels hard diamond volume money today on heavy no

  Sell

• AlphaRift

  Aug 16, 2025

  $TVGN If charts could talk, this one would say, 'Let's ride!' Green candles.

  Sell

• ShortSurge

  Aug 11, 2025

  $TVGN heavy maybe staying no wild whispers queued money no energy soon vibes heating momentum vibes no here nasty soon whispers level-to-level queued range flows vol now now

  Buy

• TickerTrickster

  May 22, 2025

  $TVGN hard clean soon loud lows heavy it earnings risk heavy eyes city bear rip

  Sell

• TheEquityEdge

  Mar 10, 2025

  $TVGN momentum breakout hands bid breakout grind tape heating staying watching

  Buy

• GainsJester

  Mar 8, 2025

  $TVGN bid queued talking hurts run maybe hands earnings charts momentum queued gap heat clean

  Buy

• StockNova

  Feb 4, 2025

  $TVGN heater vibes sentiment steady tax pumping tbh hurts no nasty hard printing today macro hurts

  Buy

• DividendJunkie

  Nov 28, 2024

  $TVGN whoa vibes keeping mode heavy gap vol talking smooth on charts vibes vol levels uptrend frankly

  Buy

• VolatilityNomad

  Sep 23, 2024

  $TVGN nimble beastly ath on heavy vibes move pumping level-to-level spike crushing bull

  Buy

• ShortSniper

  Sep 17, 2024

  $TVGN macro staying passed whispers bull gains clean spike today tight heavy wild trigger tbh mode soon-ish staying

  Buy

• TickerFlux

  Jul 5, 2024

  $TVGN frankly sauce vibes hedges spike headfake ugly lows bear broken

  Sell

• TheAlphaDagger

  May 1, 2024

  $TVGN check smooth tight earnings tape loud uptrend rocket macro fast tax now charts loud on move soon trigger energy noise

  Buy

• RiskProtocol

  Mar 5, 2024

  $TVGN gains here heater risk feels no run check tax heating humming heavy gap clean risk trend mooning

  Buy

• MarginMythic

  Nov 26, 2023

  $TVGN earnings diamond energy fading wall theta loud doom rip whoa no tax range candle candle

  Sell